Connect with us

Press Release

Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer

Published

2 years ago

on

–News Direct–

By Jeremy Golden, Benzinga

Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ: CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023.

The randomized, controlled clinical trial is specifically looking into the safety and efficacy of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection if possible in borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Very encouraging results were recently reported by the Needham, Massachusetts-based company.

Patients reached an estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in the control group in PDAC. At 24 months, the survival rate was 71.4% in CAN-2409 treated patients compared to only 16.7% in the control group after chemoradiation. Thus, prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable PDAC. Importantly, 4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with 2 patients surviving more than 50.0 months from enrollment. Only 1 out of 6 patients in the randomized control SoC chemotherapy group remained alive at the data cut-off (50.6 months).

No new safety signals were observed, providing further support that multiple injections of CAN-2409 are generally well tolerated. Additionally, there were no dose-limiting toxicities or cases of pancreatitis reported.

Previous analysis of resected tumors showed dense aggregates of immune cells including CD8+, cytotoxic tumor-infiltrating lymphocytes and dendritic cells in PDAC tissue after CAN-2409 administration. This reinforces the potential of CAN-2409 to activate a robust antitumoral immune response in patients with cancer also in cold, immunosuppressive tumors like PDAC.

Given the frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed, said Garrett Nichols, MD, MS, Chief Medical Officer of Candel. We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data in this randomized clinical trial. CAN-2409 was generally well tolerated without significant additional local or systemic toxicity when added to SoC chemoradiation.

Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf, replication-defective adenovirus designed to induce an individualized, systemic immune response against the tumor. Because of its versatility, CAN-2409 has the potential to treat a broad range of solid tumors. More than 1,000 patients have been dosed with CAN-2409 to date, with a favorable reported tolerability profile and proof of concept in each indication that the company is currently pursuing.

CAN-2409 is injected directly into the tumor or target tissue using a localized injection method that is akin to the standard approach for in situ vaccination to elicit an immune response against the injected tumor and uninjected metastases.

Long-term survival data in PDAC was recently updated with eight months of further follow-up since the first analysis was presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting. Based on the data presented at SITC, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to Candel Therapeutics for CAN-2409 in combination with valacyclovir for the treatment of patients with PDAC in December 2023. More recently, the FDA also granted Orphan Drug Designation.

The failure of conventional immunotherapy to improve outcomes in pancreatic cancer is attributed to the highly immunosuppressive tumor microenvironment, which is largely devoid of immune cells, said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. The immunological changes induced by CAN-2409, evident in the pancreatic tissue and the peripheral blood after administration, suggest that CAN-2409 is able to change the balance between the tumor and the patients anti-tumor immune response, which can convert progressive cancer into a chronic disease associated with improved survival.

Featured photo by National Cancer Institute on Unsplash.

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Aljanae Reynolds

+1 617-916-5445

areynolds@wheelhouselsa.com

Company Website

https://www.candeltx.com/

View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-reports-positive-data-from-phase-2-trial-of-can-2409-in-borderline-resectable-pancreatic-cancer-425692953

Candel Therapeutics

comtex tracking

COMTEX_453283087/2655/2024-06-03T08:31:08

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

IRIS Vision Capital Strengthens Its Global Position as a Venture Strategy Platform Connecting Investors, Funds, and Founders Across Europe, Africa, and the United States

Published

4 hours ago

on

December 10, 2025

By

IRIS Vision Capital, a venture strategy and cross-border investment platform operating across Portugal, Finland, broader Europe, Africa, and the United States, is expanding its role in global deal-making. Led by venture strategist Steven Dossou, the firm connects founders, investors, and fund managers through investment-readiness programs, curated deal-flow, and strategic matchmaking—including its AETHER digital platform and the high-intent Deals Only event. IRIS supports fundraising, co-investment, and M&A exploration across multiple innovation ecosystems.

United Kingdom, 10th Dec 2025 — IRIS Vision Capital, a venture strategy and cross-border investment platform, is expanding its role as a key connector for founders, investors, and fund managers seeking structured pathways for fundraising, deal-making, and M&A exploration. Operating across Portugal, Finland, additional European markets, select African regions, and the United States, the firm is emerging as a strategic partner for institutions navigating increasingly complex early-stage and growth-stage investment environments.

Founded by venture strategist and international keynote speaker Steven Dossou, IRIS Vision Capital provides clarity, structure, and cross-border connectivity for stakeholders aiming to deploy or raise capital, identify acquisition opportunities, collaborate across markets, and enhance investor readiness.

Through targeted programs, digital platforms, curated deal-making events, and partnership-driven ecosystem work, IRIS Vision Capital is positioning itself as a comprehensive enabler for transaction-oriented innovation activity.

A Venture Strategy Platform Built Around Deal-Making and Capital Enablement

IRIS Vision Capital operates beyond the traditional accelerator or advisory model, offering a structured, market-bridging approach that serves founders, investors, fund managers, corporate innovators, and acquisition-focused buyers.

The firm’s work centers on four integrated pillars:

1. Founder Enablement & Capital Readiness

IRIS equips founders with the tools and frameworks required to engage confidently with investors and acquirers, including:

  • Pitch strategy and investor storytelling
  • Leadership & communication development
  • Traction strategy and revenue enablement
  • Valuation, financial modeling, and governance
  • Due diligence preparation for equity and M&A discussions

This prepares founders not only for fundraising but also for growth-stage transactions and strategic opportunities.

2. Investor Development & Fund Manager Support

IRIS supports emerging angel investors, syndicates, LPs, and fund managers through:

  • Deal assessment and due diligence training
  • Portfolio strategy and risk navigation
  • Cross-border investment insights
  • Access to structured, high-quality deal-flow
  • Participation in curated deal rooms and investor circles

These initiatives strengthen local and international investor communities while improving the quality of early-stage deal-making.

3. Deal-Flow Facilitation, Co-Investments & M&A Exploration

Positioned as a cross-border conduit, IRIS Vision Capital facilitates:

  • Founder ↔ investor matching
  • Co-investment opportunities between funds
  • Strategic introductions for potential acquisitions
  • Corporate–startup innovation collaborations
  • Cross-market expansion and partnership development

This includes supporting U.S. and European investors seeking vetted opportunities in Europe and Africa, as well as assisting African founders navigating U.S. and EU investor markets.

4. Cross-Border Ecosystem Development

With a presence across Portugal, Finland, southern Europe, Africa, and U.S. hubs, IRIS collaborates with:

  • Universities and innovation centers
  • Startup accelerators
  • Corporate innovation teams
  • Angel networks and family offices
  • Economic development agencies
  • Fund managers exploring new markets

This multi-market approach allows IRIS Vision Capital to identify emerging patterns, bridge ecosystem gaps, and facilitate the movement of capital, talent, and opportunities.

AETHER and Deals Only: Two Flagship Initiatives Driving IRIS Vision Capital’s Growth

AETHER – A Digital Venture Matching Platform

AETHER is IRIS Vision Capital’s forthcoming digital platform designed to streamline founder–investor matching using structured profiling, interest-based filters, and readiness indicators. The platform will serve:

  • LPs & GPs
  • Angel syndicates
  • Family offices
  • Corporate venture teams
  • Acquisition-focused buyers
  • Investment-ready founders

AETHER is positioned to become an efficient interface for cross-border deal sourcing and investor alignment.

Deals Only – A High-Intent Global Deal-Making Event

Deals Only, IRIS Vision Capital’s curated online event, is engineered specifically for capital transactions—removing panels, keynote speeches, and general networking to focus exclusively on deal-making.

The event brings together:

  • Institutional investors (LPs, GPs, family offices)
  • Venture capital firms
  • Angel investors
  • Corporate innovators and M&A teams
  • Founders actively raising capital or exploring strategic partnerships

Through pre-matched private deal rooms and structured follow-up systems, Deals Only aims to accelerate investment decisions and create tangible outcomes across multiple markets.

Led by Global Venture Strategist Steven Dossou

With professional experience spanning Europe, Africa, the Middle East, and North America, Steven Dossou has established himself as a recognized educator and strategist in venture investing, leadership development, and cross-border ecosystem building.

“Founders, investors, and institutions need more than visibility—they need clarity, structure, and meaningful connections that lead to real deals,” said Dossou. “IRIS Vision Capital exists to bring discipline to early-stage and growth-stage investing, and to create reliable pathways between regions that historically operated in silos.”

Shaping the Future of Cross-Border Venture Activity

As global innovation markets continue to evolve, IRIS Vision Capital is preparing to scale:

  • Its digital platforms
  • Its event portfolio
  • Its partnerships with universities, funds, and ecosystem builders
  • Its deal-making infrastructure across Europe, Africa, and the United States

The firm aims to play a growing role in strengthening early-stage and growth-stage venture markets, enabling capital movement, and supporting M&A activity where strategic fit emerges.

About IRIS Vision Capital

IRIS Vision Capital is a global venture strategy platform enabling founders, investors, and institutions to engage in fundraising, deal-making, and cross-border M&A activity. Through investment readiness programs, investor education, curated deal-flow, strategic partnerships, and digital matchmaking solutions, IRIS supports venture ecosystems across Portugal, Finland, broader Europe, Africa, and the United States.

Website: www.irisvisioncapital.com
Collaboration Inquiries: info@irisvisioncapital.com
Investor Relations: partnerships@irisvisioncapital.com

Media Contact

Organization: IRIS Vision Capital

Contact Person: Elizabeth Queta

Website: https://irisvisioncapital.com/

Email: Send Email

Contact Number: +447418358394

Address:70-75 Sheldon Road

Address 2: London, Greater London

City: London

State: Greater London

Country:United Kingdom

Release id:38859

Disclaimer: This press release contains forward-looking statements that reflect current expectations, estimates, and projections. Actual results or outcomes may differ materially due to market conditions, regulatory changes, and other factors. This information is provided for general informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation of an offer to buy any securities.

The post IRIS Vision Capital Strengthens Its Global Position as a Venture Strategy Platform Connecting Investors, Funds, and Founders Across Europe, Africa, and the United States appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

AgriFi Brings Farmland On-Chain with Its IoT and Blockchain-Powered Marketplace

Published

4 hours ago

on

December 10, 2025

By

Estonia, 10th December 2025, ZEX PR WIRE–AgriFi, the decentralized agriculture finance ecosystem, a blockchain-integrating farmland marketplace, a unified platform that combines IoT data, AI-driven analytics, and tokenized ownership to create the transparent agricultural investment network.

  

AgriFi’s mission is to connect farmers, investors, and agricultural data through a verifiable, blockchain-secured infrastructure that enhances transparency, accessibility, and sustainability across the global farming landscape.

A Marketplace Rooted in Data and Trust

Traditional farmland markets often suffer from limited access, data opacity, and manual verification processes. AgriFi’s marketplace will resolve these inefficiencies by merging blockchain’s immutability and auditability with IoT-based intelligence to create data-verified farmland portfolios, ensuring that every farmland token listed on the platform is backed by verifiable, real-time performance metrics.

Each land parcel integrated into the AgriFi ecosystem is associated with on-chain metadata that includes key agricultural parameters such as soil health, water usage, and crop productivity; all verified through IoT devices and Chainlink-compatible oracles.

“Transparency and traceability aren’t features; they’re fundamentals,” said Veronica Trump, CMO at AgriFi. “We’re on a mission to create a marketplace where every investor can see, verify, and own a part of the agricultural industry with confidence.”

Core Components of the Farmland Marketplace

  1. IoT-Integrated Farm Monitoring: AgriFi’s marketplace will aggregates real-time data from connected IoT devices, tracking parameters such as soil moisture, water usage, and crop growth. This integration ensures that each tokenized asset is backed by authentic, measurable performance data, supporting investor trust and accountability.
  2. Blockchain-Based Ownership: Each listed farmland parcel will be tokenized through smart contracts  on the Polygon Network, allowing fractional investment, transparent ownership records, and instant on-chain transfers. This lowers entry barriers for retail investors while ensuring traceable and compliant asset management.
  3. Profit and Performance Dashboard: Investors can monitor productivity metrics, yield performance, and staking rewards directly linked to their AGF Token holdings. These analytics are powered by data from verified farms, ensuring that returns correspond to real-world agricultural outcomes.
  4. Compliance and Legal Security: The system integrates KYC/AML verification, asset certification, and immutable storage of legal documents via IPFS/Filecoin, ensuring compliance and investor protection.
  5. Cross-Border Accessibility: Through fiat on-ramps, decentralized exchange (DEX) integration, and a mobile-optimized interface, AgriFi enables global investors to access tokenized farmland opportunities without intermediaries.

The Future of Farmland Ownership

By merging IoT intelligence, blockchain verification, and DeFi mechanisms, it delivers:

  • Full Transparency: Real-time data and blockchain records for every farm asset.
  • Global Liquidity: Fractional farmland ownership tradable on Polygon-based DEXs such as QuickSwap.
  • Investor Empowerment: Access to live farm analytics, profit dashboards, and verified yields.
  • Sustainable Growth:  Integration of ESG and traceability standards, including future carbon and water footprint tokens.

This unified, trust-based ecosystem is a significant leap forward in data-driven, sustainable agriculture, creating value for both local farmers and global investors.

Seamless Crypto Trading

AgriFi’s Decentralized Exchange (DEX) allows users to seamlessly swap AGF tokens for leading cryptocurrencies such as USDT, ETH, and MATIC. Unlike centralized exchanges, AgriFi’s DEX ensures a secure, transparent, and censorship-resistant trading environment where all transactions occur directly between users, eliminating intermediaries and reducing costs.

The user-friendly interface is designed for accessibility, so even newcomers can execute trades within a few clicks. Since users retain full custody of their funds, this decentralized structure minimizes risks of centralized hacks, withdrawal freezes, or fund mismanagement.

Earn Rewards Through Liquidity Provision

Beyond trading, AgriFi enables users to earn passive income by providing liquidity to its DEX. When users deposit token pairs, such as AGF-USDT, AGF-ETH, or AGF-MATIC, they receive Liquidity Provider (LP) tokens, representing their stake in the pool and entitlement to a share of transaction fees.

Liquidity providers not only earn yield but also strengthen the DEX’s market depth and stability, ensuring smoother trades with minimal slippage. This structure reinforces AgriFi’s community-driven liquidity model, empowering users to benefit directly from the platform’s trading activity while contributing to the ecosystem’s resilience.

About Agrifi

Agrifi is driving an agricultural revolution, harnessing blockchain technology to transform the agricultural supply chain. Our mission is to enhance transparency, efficiency, and sustainability in agriculture while empowering farmers and supporting small-scale agricultural practices.

Join us on this exciting journey to explore the future of agriculture while potentially enhancing the value of your AGF tokens. We’re not just redefining agricultural finance; we’re revolutionizing the future of farming and food production.

Ready to start staking your AGF tokens? Visit our website at https://agrifi.tech/for detailed steps on how to stake your tokens. Stay connected with us on Telegram, Twitter, Facebook, and Instagram for the latest updates and community discussions.

Follow Us on:

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Defining the Future: ECI Awards Joins Forces with Petal Ads to Open a New Era of Digital Innovation

Published

4 hours ago

on

December 10, 2025

By

Shanghai, China, 10th Dec 2025 – The ECI Awards 2025 final judging session, hailed as the “Nobel Prize of the global digital innovation field,” was held in Shanghai. Centered on the theme “Defining the Future,” this year’s event partnered with the all-scenario intelligent marketing platform ” Petal Ads ” to convene leaders from brand enterprises, top scholars from research institutions, and international capital investors across the Asia-Pacific region and beyond. The gathering focused on in-depth evaluation across 14 cutting-edge innovation tracks, highlighting breakthrough applications of Artificial Intelligence (AI) technology in areas such as brand globalization, digital art, and charitable initiatives. This underscored the core philosophy of “application value-driven innovation.”

 

Strategic Partnership: Building an Open and Collaborative Innovation Ecosystem

As the strategic partner for this event,  Petal Ads and the ECI Awards jointly champion the innovative vision of “Defining the Future.” They aim to foster the integration of technology and industrial practice through open collaboration, reinforcing the judging criteria oriented toward “actionable innovation.” Based on a shared understanding of digital economic trends, the two parties are working together to build an international platform for innovation exchange. The representative from Petal Ads conveyed high praise and great expectations for the collaboration with the ECI Awards.

 

Authoritative Judging Panel: Global Wisdom from Diverse Backgrounds

This year’s final jury boasts comprehensive coverage across “government, industry, academia, research, and investment,” highlighting its international and diverse character:

· Brand Enterprise Representatives: Digital transformation leaders from globally renowned brands, focusing on how AI empowers cross-border commercial scenarios, such as intelligent marketing tools and supply chain optimization solutions.

· Technology Innovation Institution Experts: Scholars from leading research institutes and universities, spearheading the assessment of technological foresight in fields like digital art and brain-computer interfaces.

· International Capital Perspective: Partners from well-known investment institutions, high-potential projects based on both capital return and social impact.

 

As Dr. Owen Lijun Jia, Global Initiator of ECI, pointed out: “The unique value of ECI lies in its focus not only on technological advancement but also on its ability to create sustainable economic and social value. It further advocates that digital innovation should embody the humanistic value of ‘tech for good’—this is precisely why the ECI International Awards are acclaimed as the ‘Nobel Prize of Innovation!’”

Highlights from 14 Innovation Tracks: AI Leads New Trends of Cross-Border Integration

Among all entries, three fields sparked extensive discussion for their dual breakthroughs in “technology + social value”:

1. AI Empowering Brand Globalization

   · Core Focus: Reducing cross-border operational costs and enhancing the efficiency of “Intelligent Chinese Manufacturing” going global through real-time translation and cultural adaptation algorithms.

   · Jury Consensus: Technological compliance and localization speed have become key competitive advantages for brand globalization.

2. The Digital Art Revolution

   · Disruptive Directions: Blockchain enabling artwork provenance tracking, and AI generative creation pushing the boundaries of traditional copyright.

   · Benchmark Practice: Digital interactive experiences for cultural heritage were recognized as “exemplars of humanities-technology integration.”

3. Future Rural Development & Public Welfare Innovation

   · Rising Star Track: Agricultural AI diagnostic systems boosting crop yields in remote areas, and VR education platforms narrowing the urban-rural knowledge gap.

   · Special Recognition: The judging panel introduced a “Sustainable Public Welfare Innovation Award” to commend praiseworthy practices of “Innovation for Good.”

The ECI “Gold Standard”: Anchored in Real-World Transformative Power

Distinct from other awards, ECI consistently employs “Innovation Effectiveness” as its core metric, requiring winning projects to demonstrate:

· Economic Efficacy: Verified business models or clear revenue pathways, e.g., an intelligent mobility solution adopted by municipal transportation systems in multiple countries.

· Social Benefit: Addressing pain points for specific groups, e.g., accessible AI-assisted elderly care devices benefiting millions of people with disabilities.

· Cultural Heritage Preservation: Promoting positive values, e.g., carbon-neutral themed games reshaping teenagers’ environmental awareness.

 “We are not seeking demos from the lab, but innovations that can truly define the future”

 summarized the ECI Judging Committee.

 

Epilogue: From Judging Panel to Ecosystem, the ECI Festival Continues the Innovation Narrative

Following the closing of the final judging session, the 11th ECI Festival is set to take place in the Greater Bay Area, centered in Guangzhou, from January 15-17 next year. It will construct a complete ecosystem chain of “evaluation, launch, and incubation.” The event will continue to connect global innovation forces, driving technological achievements from concept to reality.

As AI moves beyond parameter competition to become a bridge connecting Chinese manufacturing with global demand, and as innovation pursues not only commercial success but also bears the mission of applying digital innovation to the inheriting of human civilization, the 2025 ECI final judging session is redefining “what constitutes truly disruptive innovation.”

About ECI Awards

The ECI Awards (Entrepreneurship, Creativity & Innovation Awards), established by the IECIA in the United States in 2014, is the first international award in the global digital economy sector to employ “The Effectiveness of Innovation” as its evaluation standard. The ECI Awards are dedicated to recognizing cases, individuals, and organizations demonstrating highly innovative application value across tracks including “Product, Model, Marketing, MarTech, AI Application, Public Welfare, ESG, Digital Retail, Future Rural Development, Brand Globalization, Digital Culture & Tourism, and Digital Art.” The ECI Awards honor not only commercially valuable innovation but, more importantly, innovation that can define the future, promote the sustainable development of human society, and embody humanistic spirit. It is renowned as the “Nobel Prize” in the field of digital economy innovation.

Media Contact

Organization: Secretary General of ECl Awards Committee

Contact Person: Faye Feng

Website: https://www.eciawards.org.cn

Email: Send Email

City: Shanghai

Country:China

Release id:38865

The post Defining the Future: ECI Awards Joins Forces with Petal Ads to Open a New Era of Digital Innovation appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us